Skip to main content
Springer Nature Link
Log in

Mendelian Causes of Autoimmunity: the Lupus Phenotype

  • Review
  • Published:
Journal of Clinical Immunology Aims and scope Submit manuscript

Abstract

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that is characterized by its large heterogeneity in terms of clinical presentation and severity. The pathophysiology of SLE involves an aberrant autoimmune response against various tissues, an excess of apoptotic bodies, and an overproduction of type-I interferon. The genetic contribution to the disease is supported by studies of monozygotic twins, familial clustering, and genome-wide association studies (GWAS) that have identified numerous risk loci. In the early 70s, complement deficiencies led to the description of familial forms of SLE caused by a single gene defect. High-throughput sequencing has recently identified an increasing number of monogenic defects associated with lupus, shaping the concept of monogenic lupus and enhancing our insights into immune tolerance mechanisms. Monogenic lupus (moSLE) should be suspected in patients with either early-onset lupus or syndromic lupus, in male, or in familial cases of lupus. This review discusses the genetic basis of monogenic SLE and proposes its classification based on disrupted pathways. These pathways include defects in the clearance of apoptotic cells or immune complexes, interferonopathies, JAK-STATopathies, TLRopathies, and T and B cell dysregulations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

Data Availability

No datasets were generated or analysed during the current study.

References

  1. Aringer M et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis. 2019;78(9):1151–9. https://doi.org/10.1136/annrheumdis-2018-214819.

    Article  PubMed  Google Scholar 

  2. Tsokos GC, Lo MS, Reis PC, Sullivan KE. New insights into the immunopathogenesis of systemic lupus erythematosus. Nat Rev Rheumatol. 2016;12(12):716–30. https://doi.org/10.1038/nrrheum.2016.186.

    Article  CAS  PubMed  Google Scholar 

  3. Lemke G. How macrophages deal with death. Nat Rev Immunol. 2019;19(9):539–49. https://doi.org/10.1038/s41577-019-0167-y.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Doran AC, Yurdagul A, Tabas I. Efferocytosis in health and disease. Nat Rev Immunol. 2020;20(4):254–67. https://doi.org/10.1038/s41577-019-0240-6.

    Article  CAS  PubMed  Google Scholar 

  5. Mehrotra P, Ravichandran KS. Drugging the efferocytosis process: concepts and opportunities. Nat Rev Drug Discov. 2022;21(8):601-620. https://doi.org/10.1038/s41573-022-00470-y.

    Article  CAS  Google Scholar 

  6. Rose T, Dörner T. Drivers of the immunopathogenesis in systemic lupus erythematosus. Best Pract Res Clin Rheumatol. 2017;31(3):321–33. https://doi.org/10.1016/j.berh.2017.09.007.

    Article  PubMed  Google Scholar 

  7. Kamphuis S, Silverman ED. Prevalence and burden of pediatric-onset systemic lupus erythematosus. Nat Rev Rheumatol. 2010;6(9):538–46. https://doi.org/10.1038/nrrheum.2010.121.

    Article  CAS  PubMed  Google Scholar 

  8. Arnaud L, Fagot J-P, Mathian A, Paita M, Fagot-Campagna A, Amoura Z. Prevalence and incidence of systemic lupus erythematosus in France: a 2010 nation-wide population-based study. Autoimmun Rev. 2014;13(11):1082–9. https://doi.org/10.1016/j.autrev.2014.08.034.

    Article  PubMed  Google Scholar 

  9. Bader-Meunier B, et al. Initial presentation of childhood-onset systemic lupus erythematosus: a French multicenter study. J Pediatr. 2005;146(5):648–53. https://doi.org/10.1016/j.jpeds.2004.12.045.

    Article  CAS  PubMed  Google Scholar 

  10. Alexander T, Hedrich CM. Systemic lupus erythematosus – are children miniature adults? Clin Immunol. 2022;234:108907. https://doi.org/10.1016/j.clim.2021.108907.

    Article  CAS  PubMed  Google Scholar 

  11. Papadimitraki ED, Isenberg DA. Childhood- and adult-onset lupus: an update of similarities and differences. Expert Rev Clin Immunol. 2009;5(4):391–403. https://doi.org/10.1586/eci.09.29.

    Article  PubMed  Google Scholar 

  12. Gutierrez-Arcelus M, Rich SS, Raychaudhuri S. Autoimmune diseases — connecting risk alleles with molecular traits of the immune system. Nat Rev Genet. 2016;17(3):160. https://doi.org/10.1038/nrg.2015.33.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Criswell LA. The genetic contribution to systemic lupus erythematosus. Bull NYU Hosp Jt Dis. 2008;66(3):176–83.

    PubMed  Google Scholar 

  14. Deapen D, et al. A revised estimate of twin concordance in systemic lupus erythematosus. Arthritis Rheum. 1992;35(3):311–8. https://doi.org/10.1002/art.1780350310.

    Article  CAS  PubMed  Google Scholar 

  15. Ulff-Møller CJ, Svendsen AJ, Viemose LN, Jacobsen S. Concordance of autoimmune disease in a nationwide Danish systemic lupus erythematosus twin cohort. Semin Arthritis Rheum. 2018;47(4):538–44. https://doi.org/10.1016/j.semarthrit.2017.06.007.

    Article  PubMed  Google Scholar 

  16. Deng Y, Tsao BP. Genetic susceptibility to systemic lupus erythematosus in the genomic era. Nat Rev Rheumatol. 2010;6(12):683–92. https://doi.org/10.1038/nrrheum.2010.176.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Cui Y, Sheng Y, Zhang X. Genetic susceptibility to SLE: recent progress from GWAS. J Autoimmun. 2013;41:25–33. https://doi.org/10.1016/j.jaut.2013.01.008.

    Article  CAS  PubMed  Google Scholar 

  18. Kozyrev SV, et al. Functional variants in the B-cell gene BANK1 are associated with systemic lupus erythematosus. Nat Genet. 2008;40(2):211–6. https://doi.org/10.1038/ng.79.

    Article  CAS  PubMed  Google Scholar 

  19. Jiang SH, et al. Functional rare and low frequency variants in BLK and BANK1 contribute to human lupus. Nat Commun. 2019;10. https://doi.org/10.1038/s41467-019-10242-9.

  20. Alkaissi H, Havarinasab S, Nielsen JB, Söderkvist P, Hultman P. Bank1 and NF-kappaB as key regulators in anti-nucleolar antibody development. PLoS ONE. 2018;13(7):e0199979. https://doi.org/10.1371/journal.pone.0199979.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Belot A, Cimaz R. Monogenic forms of systemic lupus erythematosus: new insights into SLE pathogenesis. Pediatr Rheumatol Online J. 2012;10(1):21. https://doi.org/10.1186/1546-0096-10-21.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Belot A, Cochat P. Monogenic systemic lupus erythematosus. Nephrol Ther. 2012;8(1):1–4. https://doi.org/10.1016/j.nephro.2011.05.003.

    Article  PubMed  Google Scholar 

  23. Belot A, et al. Contribution of rare and predicted pathogenic gene variants to childhood-onset lupus: a large, genetic panel analysis of British and French cohorts. Lancet Rheumatol. 2020;2(2):e99–109. https://doi.org/10.1016/S2665-9913(19)30142-0.

    Article  PubMed  Google Scholar 

  24. Agnello V, De Bracco MM, Kunkel HG. Hereditary C2 deficiency with some manifestations of systemic lupus erythematosus. J Immunol Baltim Md 1950. 1972;108(3):837–40.

    CAS  Google Scholar 

  25. Moncada B, Day NKB, Good RA, Windhorst DB. Lupus-erythematosus-like syndrome with a familial defect of complement. N Engl J Med. 1972;286(13):689–93. https://doi.org/10.1056/nejm197203302861304.

    Article  CAS  PubMed  Google Scholar 

  26. Santer DM, et al. C1q deficiency leads to the defective suppression of IFN-alpha in response to nucleoprotein containing immune complexes. J Immunol Baltim Md 1950. 2010;185(8):4738–49. https://doi.org/10.4049/jimmunol.1001731.

    Article  CAS  Google Scholar 

  27. Batu ED, et al. Whole exome sequencing in early-onset systemic lupus erythematosus. J Rheumatol. 2018;45(12):1671–9. https://doi.org/10.3899/jrheum.171358.

    Article  CAS  PubMed  Google Scholar 

  28. Abel G, Agnello V. Complement deficiency and systemic lupus erythematosus. Elsevier; 2004. pp. 173–201. https://doi.org/10.1016/b9-78-012433-9/01950-0090.

  29. Lintner KE, et al. Early components of the complement classical activation pathway in human systemic autoimmune diseases. Front Immunol. 2016;7:36. https://doi.org/10.3389/fimmu.2016.00036.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Tusseau M, et al. DNASE1L3 deficiency, new phenotypes, and evidence for a transient type I IFN signaling. J Clin Immunol. 2022;42(6):1310–20. https://doi.org/10.1007/s10875-022-01287-5.

    Article  CAS  PubMed  Google Scholar 

  31. Sisirak V, et al. Digestion of chromatin in apoptotic cell microparticles prevents autoimmunity. Cell. 2016;166(1):88–101. https://doi.org/10.1016/j.cell.2016.05.034.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Al-Mayouf SM, et al. Loss-of-function variant in DNASE1L3 causes a familial form of systemic lupus erythematosus. Nat Genet. 2011;43(12):1186–8. https://doi.org/10.1038/ng.975.

    Article  CAS  PubMed  Google Scholar 

  33. Tsokos GC. Systemic lupus erythematosus. N Engl J Med. 2011;365:2110–21. https://doi.org/10.1056/NEJMra1100359.

  34. Aicardi J, Goutières F. A Progressive familial encephalopathy in infancy with calcifications of the basal ganglia and chronic cerebrospinal fluid lymphocytosis. Ann Neurol. 1984;15(1):49–54. https://doi.org/10.1002/ana.410150109.

    Article  CAS  PubMed  Google Scholar 

  35. Lebon P, Badoual J, Ponsot G, Goutières F, Hémeury-Cukier F, Aicardi J. Intrathecal synthesis of interferon-alpha in infants with progressive familial encephalopathy. J Neurol Sci. 1988;84(2):201–8. https://doi.org/10.1016/0022-510X(88)90125-6.

    Article  CAS  PubMed  Google Scholar 

  36. Crow YJ, Rehwinkel J. Aicardi-Goutières syndrome and related phenotypes: linking nucleic acid metabolism with autoimmunity. Hum Mol Genet. 2009;18(R2):R130–6. https://doi.org/10.1093/hmg/ddp293.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Crow YJ, et al. Mutations in the gene encoding the 3′-5′ DNA exonuclease TREX1 cause Aicardi-Goutières syndrome at the AGS1 locus. Nat Genet. 2006;38(8):Art. no. 8. https://doi.org/10.1038/ng1845.

    Article  CAS  Google Scholar 

  38. Crow YJ. Type I interferonopathies: a novel set of inborn errors of immunity. Ann N Y Acad Sci. 2011;1238(1):91–8. https://doi.org/10.1111/j.1749-6632.2011.06220.x.

    Article  CAS  PubMed  Google Scholar 

  39. Crow YJ, Stetson DB. The type I interferonopathies: 10 years on. Nat Rev Immunol. 2022;22(8):471-483. https://doi.org/10.1038/s41577-021-00633-9.

    Article  CAS  Google Scholar 

  40. Rice GI, Rodero MP, Crow YJ. Human disease phenotypes associated with mutations in TREX1. J Clin Immunol. 2015;35(3):235–43. https://doi.org/10.1007/s10875-015-0147-3.

    Article  CAS  PubMed  Google Scholar 

  41. Richards A, et al. C-terminal truncations in human 3’-5’ DNA exonuclease TREX1 cause autosomal dominant retinal vasculopathy with cerebral leukodystrophy. Nat Genet. 2007;39(9):1068–70. https://doi.org/10.1038/ng2082.

    Article  CAS  PubMed  Google Scholar 

  42. Liu Y, et al. Activated STING in a vascular and pulmonary syndrome. N Engl J Med. 2014;371(6):507–18. https://doi.org/10.1056/NEJMoa1312625.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. König N, et al. Familial chilblain lupus due to a gain-of-function mutation in STING. Ann Rheum Dis. 2017;76(2):468–72. https://doi.org/10.1136/annrheumdis-2016-209841.

    Article  CAS  PubMed  Google Scholar 

  44. Jeremiah N, et al. Inherited STING-activating mutation underlies a familial inflammatory syndrome with lupus-like manifestations. J Clin Invest. 2014;124(12):5516–20. https://doi.org/10.1172/JCI79100.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Lepelley A, et al. Mutations in COPA lead to abnormal trafficking of STING to the Golgi and interferon signaling. J Exp Med. 2020;217(11):e20200600. https://doi.org/10.1084/jem.20200600.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Watkin LB, et al. COPA mutations impair ER-Golgi transport causing hereditary autoimmune-mediated lung disease and arthritis. Nat Genet. 2015;47(6):654–60. https://doi.org/10.1038/ng.3279.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Briggs TA, et al. Spondyloenchondrodysplasia due to mutations in ACP5: a comprehensive survey. J Clin Immunol. 2016;36:220–34. https://doi.org/10.1007/s10875-016-0252-y.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Rodero MP, et al. Type I interferon-mediated autoinflammation due to DNase II deficiency. Nat Commun. 2017;8(1):2176. https://doi.org/10.1038/s41467-017-01932-3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Thaventhiran JED, et al. Whole-genome sequencing of a sporadic primary immunodeficiency cohort. Nature. 2020;583(7814):Art. no. 7814. https://doi.org/10.1038/s41586-020-2265-1.

    Article  CAS  Google Scholar 

  50. Hadjadj J, et al. Early-onset autoimmunity associated with SOCS1 haploinsufficiency. Nat Commun. 2020;11:5341. https://doi.org/10.1038/s41467-020-18925-4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Gruber C, et al. IL4Rα and IL17A blockade rescue autoinflammation in SOCS1 haploinsufficiency. J Clin Immunol. 2023;44(1):36. https://doi.org/10.1007/s10875-023-01635-z.

    Article  CAS  PubMed  Google Scholar 

  52. Rodari MM, et al. Insights into the expanding intestinal phenotypic spectrum of SOCS1 haploinsufficiency and therapeutic options. J Clin Immunol. 2023. https://doi.org/10.1007/s10875-023-01495-7.

    Article  PubMed  PubMed Central  Google Scholar 

  53. Parlato M, et al. Loss-of-function mutation in PTPN2 causes aberrant activation of JAK signaling via STAT and very early onset intestinal inflammation. Gastroenterology. 2020;159(5):1968-1971.e4. https://doi.org/10.1053/j.gastro.2020.07.040.

    Article  CAS  PubMed  Google Scholar 

  54. Okada S, et al. Human STAT1 gain-of-function heterozygous mutations: chronic mucocutaneous candidiasis and type I interferonopathy. J Clin Immunol. 2020;40(8):1065–81. https://doi.org/10.1007/s10875-020-00847-x.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Heterozygous STAT1 gain-of-function mutations underlie an unexpectedly broad clinical phenotype | Blood | American Society of Hematology.   https://ashpublications-org.proxy.insermbiblio.inist.fr/blood/article/127/25/3154/35201/Heterozygous-STAT1-gain-of-function-mutations. Accessed 17 Nov 2023.

  56. Brown GJ, et al. TLR7 gain-of-function genetic variation causes human lupus. Nature. 2022;605(7909):349–56. https://doi.org/10.1038/s41586-022-04642-z.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Xie C, et al. De novo PACSIN1 gene variant found in childhood lupus and a role for PACSIN1/TRAF4 complex in toll-like receptor 7 activation. Arthritis Rheumatol Hoboken NJ. 2023;75(6):1058–71. https://doi.org/10.1002/art.42416.

    Article  CAS  Google Scholar 

  58. Wolf C, et al. UNC93B1 variants underlie TLR7-dependent autoimmunity. Sci Immunol. 2024;eadi9769. https://doi.org/10.1126/sciimmunol.adi9769.

  59. Rieux-Laucat F, et al. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science. 1995;268(5215):1347–9. https://doi.org/10.1126/science.7539157.

    Article  CAS  PubMed  Google Scholar 

  60. Wu J, Wilson J, He J, Xiang L, Schur PH, Mountz JD. Fas ligand mutation in a patient with systemic lupus erythematosus and lymphoproliferative disease. J Clin Invest. 1996;98(5):1107–13. https://doi.org/10.1172/JCI118892.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Vaishnaw AK, et al. The spectrum of apoptotic defects and clinical manifestations, including systemic lupus erythematosus, in humans with CD95 (Fas/APO-1) mutations. Arthritis Rheum. 1999;42(9):1833–42. https://doi.org/10.1002/1529-0131(199909)42:9%3c1833::AID-ANR7%3e3.0.CO;2-Q.

    Article  CAS  PubMed  Google Scholar 

  62. Rieux-Laucat F. What’s up in the ALPS. Curr Opin Immunol. 2017;49:79–86. https://doi.org/10.1016/j.coi.2017.10.001.

    Article  CAS  PubMed  Google Scholar 

  63. Kuehn HS, Boast B, Rosenzweig SD. Inborn errors of human IKAROS: LOF and GOF variants associated with primary immunodeficiency. Clin Exp Immunol. 2023;212(2):129–36. https://doi.org/10.1093/cei/uxac109.

    Article  PubMed  Google Scholar 

  64. Su G, et al. Analysis of five cases of monogenic lupus related to primary immunodeficiency diseases. Inflamm Res Off J Eur Histamine Res Soc Al. 2021;70(10–12):1211–6. https://doi.org/10.1007/s00011-021-01479-6.

    Article  CAS  Google Scholar 

  65. Walter JE, et al. Impaired receptor editing and heterozygous RAG2 mutation in a patient with systemic lupus erythematosus and erosive arthritis. J Allergy Clin Immunol. 2015;135(1):272–3. https://doi.org/10.1016/j.jaci.2014.07.063.

    Article  CAS  PubMed  Google Scholar 

  66. Belot A, et al. Protein kinase cδ deficiency causes mendelian systemic lupus erythematosus with B cell-defective apoptosis and hyperproliferation. Arthritis Rheum. 2013;65(8):2161–71. https://doi.org/10.1002/art.38008.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Jefferson L, et al. Phenotypic variability in PRKCD: a review of the literature. J Clin Immunol. 2023. https://doi.org/10.1007/s10875-023-01579-4.

    Article  PubMed  Google Scholar 

  68. Neehus A-L, et al. Impaired respiratory burst contributes to infections in PKCδ-deficient patients. J Exp Med. 2021;218(9):e20210501. https://doi.org/10.1084/jem.20210501.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Bader-Meunier B, et al. Are RASopathies new monogenic predisposing conditions to the development of systemic lupus erythematosus? Case report and systematic review of the literature. Semin Arthritis Rheum. 2013;43(2):217–9. https://doi.org/10.1016/j.semarthrit.2013.04.009.

    Article  PubMed  Google Scholar 

  70. Quaio CRDC, et al. Autoimmune disease and multiple autoantibodies in 42 patients with RASopathies. Am J Med Genet A. 2012;158A(5):1077–82. https://doi.org/10.1002/ajmg.a.35290.

    Article  CAS  PubMed  Google Scholar 

  71. Oliveira JB, et al. NRAS mutation causes a human autoimmune lymphoproliferative syndrome. Proc Natl Acad Sci. 2007;104(21):8953–8. https://doi.org/10.1073/pnas.0702975104.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Niemela JE, et al. Somatic KRAS mutations associated with a human nonmalignant syndrome of autoimmunity and abnormal leukocyte homeostasis. Blood. 2011;117(10):2883–6. https://doi.org/10.1182/blood-2010-07-295501.

    Article  PubMed  PubMed Central  Google Scholar 

  73. Eni-Aganga I, Lanaghan ZM, Balasubramaniam M, Dash C, Pandhare J. PROLIDASE: a review from discovery to its role in health and disease. Front Mol Biosci. 2021;8:723003. https://doi.org/10.3389/fmolb.2021.723003.

  74. Klar A, et al. Prolidase deficiency: it looks like systemic lupus erythematosus but it is not. Eur J Pediatr. 2010;169(6):727–32. https://doi.org/10.1007/s00431-009-1102-1.

    Article  PubMed  Google Scholar 

  75. Hodgson R, et al. Prolidase deficiency causes spontaneous T cell activation and lupus-like autoimmunity. J Immunol Author Choice. 2023;210(5):547. https://doi.org/10.4049/jimmunol.2200212.

    Article  CAS  Google Scholar 

  76. Rossignol F, et al. Quantitative analysis of the natural history of prolidase deficiency: description of 17 families and systematic review of published cases. Genet Med Off J Am Coll Med Genet. 2021;23(9):1604. https://doi.org/10.1038/s41436-021-01200-2.

    Article  Google Scholar 

  77. He Y, et al. P2RY8 variants in lupus patients uncover a role for the receptor in immunological tolerance. J Exp Med. 2022;219(1):e20211004. https://doi.org/10.1084/jem.20211004.

    Article  CAS  PubMed  Google Scholar 

  78. Tusseau M, Belot A. ‘P2RY8-son’ break of tolerance promotes SLE. J Exp Med. 2022;219(1):e20211972. https://doi.org/10.1084/jem.20211972.

    Article  CAS  PubMed  Google Scholar 

  79. Elhani I, Riller Q, Boursier G, Hentgen V, Rieux-Laucat F, Georgin-Lavialle S. A20 haploinsufficiency: a systematic review of 177 cases. J Invest Dermatol. 2023. https://doi.org/10.1016/j.jid.2023.12.007.

    Article  PubMed  Google Scholar 

  80. Xu L, et al. Loss-of-function variants in SAT1 cause X-linked childhood-onset systemic lupus erythematosus. Ann Rheum Dis. 2022;81(12):1712–21. https://doi.org/10.1136/ard-2022-222795.

    Article  CAS  PubMed  Google Scholar 

  81. Boussard C, et al. DOCK11 deficiency in patients with X-linked actinopathy and autoimmunity. Blood. 2023.  https://doi.org/10.1182/blood.2022018486.

  82. Block J, et al. Systemic inflammation and normocytic anemia in DOCK11 deficiency. N Engl J Med. 2023;389(6):527–39. https://doi.org/10.1056/NEJMoa2210054.

    Article  CAS  PubMed  Google Scholar 

  83. Pescarmona R, et al. Comparison of RT-qPCR and Nanostring in the measurement of blood interferon response for the diagnosis of type I interferonopathies. Cytokine. 2019;113:446–52. https://doi.org/10.1016/j.cyto.2018.10.023.

    Article  CAS  PubMed  Google Scholar 

  84. Wahadat MJ, et al. Serum IFNα2 levels are associated with disease activity and outperform IFN-I gene signature in a longitudinal childhood-onset SLE cohort. Rheumatol Oxf Engl. 2023;62(8):2872–9. https://doi.org/10.1093/rheumatology/keac698.

    Article  CAS  Google Scholar 

  85. Nombel A, et al. Assessment of type I interferon response in routine practice in France in 2022. RMD Open. 2023; 9. https://doi.org/10.1136/rmdopen-2023-003211.

  86. Rodríguez-Carrio J, et al. 2022 EULAR points to consider for the measurement, reporting and application of IFN-I pathway activation assays in clinical research and practice. Ann Rheum Dis. 2023;82(6):754–62. https://doi.org/10.1136/ard-2022-223628.

    Article  CAS  PubMed  Google Scholar 

  87. Rice GI, et al. Assessment of interferon-related biomarkers in Aicardi-Goutières syndrome associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, and ADAR: a case-control study. Lancet Neurol. 2013;12(12):1159–69. https://doi.org/10.1016/S1474-4422(13)70258-8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  88. Picard C, et al. Anti-C1q autoantibodies as markers of renal involvement in childhood-onset systemic lupus erythematosus. Pediatr Nephrol. 2017;32(9):1537–45. https://doi.org/10.1007/s00467-017-3646-z.

    Article  PubMed  Google Scholar 

  89. Hartl J, et al. Autoantibody-mediated impairment of DNASE1L3 activity in sporadic systemic lupus erythematosus. J Exp Med. 2021;218(5):e20201138. https://doi.org/10.1084/jem.20201138.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  90. Salzer E, et al. B-cell deficiency and severe autoimmunity caused by deficiency of protein kinase C δ. Blood. 2013;121(16):3112–6. https://doi.org/10.1182/blood-2012-10-460741.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  91. Kuehn HS, et al. Loss-of-function of the protein kinase C δ (PKCδ) causes a B-cell lymphoproliferative syndrome in humans. Blood. 2013;121(16):3117–25. https://doi.org/10.1182/blood-2012-12-469544.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  92. Lei L, et al. Successful use of ofatumumab in two cases of early-onset juvenile SLE with thrombocytopenia caused by a mutation in protein kinase C δ. Pediatr Rheumatol. 2018;16(1):61. https://doi.org/10.1186/s12969-018-0278-1.

    Article  Google Scholar 

  93. Gu H, et al. Sirolimus is effective in autoimmune lymphoproliferative syndrome-type III: a pedigree case report with homozygous variation PRKCD. Int J Immunopathol Pharmacol. 2021;35:20587384211025936. https://doi.org/10.1177/20587384211025934.

    Article  PubMed  PubMed Central  Google Scholar 

  94. Moreews M, et al. mTOR activation underlies enhanced B cell proliferation and autoimmunity in PrkcdG510S/G510S mice. J Immunol. 2023;210:1209–21. https://doi.org/10.4049/jimmunol.2200818.

    Article  CAS  PubMed  Google Scholar 

  95. Akbar L, Alsagheir R, Al-Mayouf SM. Efficacy of a sequential treatment by belimumab in monogenic systemic lupus erythematosus. Eur J Rheumatol. 2020;7(4):184–9. https://doi.org/10.5152/eurjrheum.2020.20087.

    Article  PubMed  PubMed Central  Google Scholar 

  96. Chen F, et al. Belimumab in childhood systemic lupus erythematosus: a review of available data. Front Immunol. 2022;13:940416. https://doi.org/10.3389/fimmu.2022.940416.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  97. Gómez-Arias PJ, Gómez-García F, Hernández-Parada J, Montilla-López AM, Ruano J, Parra-Peralbo E. Efficacy and safety of Janus kinase inhibitors in type I interferon-mediated monogenic autoinflammatory disorders: a scoping review. Dermatol Ther. 2021;11(3):733–50. https://doi.org/10.1007/s13555-021-00517-9.

    Article  Google Scholar 

  98. Berrada KR, et al. Lung transplantation under a Janus kinase inhibitor in three patients with SAVI syndrome. J Clin Immunol. 2023. https://doi.org/10.1007/s10875-023-01595-4.

    Article  PubMed  Google Scholar 

  99. Anifrolumab normalizes the type I interferon signature in a cohort of patients with type I interferonopathies. ACR meeting abstracts. https://acrabstracts.org/abstract/anifrolumab-normalizes-the-type-i-interferon-signature-in-a-cohort-of-patients-with-type-i-interferonopathies/. Accessed 17 Dec 2023.

  100. Brodszki N, et al. European Society for Immunodeficiencies (ESID) and European reference network on rare primary immunodeficiency, autoinflammatory and autoimmune diseases (ERN RITA) complement guideline: deficiencies, diagnosis, and management. J Clin Immunol. 2020;40(4):576–91. https://doi.org/10.1007/s10875-020-00754-1.

    Article  PubMed  PubMed Central  Google Scholar 

  101. Mackensen A, et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat Med. 2022;28(10):10. https://doi.org/10.1038/s41591-022-02017-5.

    Article  CAS  Google Scholar 

  102. Mougiakakos D, et al. CD19-targeted CAR T cells in refractory systemic lupus erythematosus. N Engl J Med. 2021;385(6):567–9. https://doi.org/10.1056/NEJMc2107725.

    Article  PubMed  Google Scholar 

  103. Li G, et al. Genetic heterogeneity in Chinese children with systemic lupus erythematosus. Clin Exp Rheumatol. 2021;39(1):214–22.

    Article  PubMed  Google Scholar 

  104. Misztal MC, et al. Genome-wide sequencing identified rare genetic variants for childhood-onset monogenic lupus. J Rheumatol. 2023;50(5):671–5. https://doi.org/10.3899/jrheum.220513.

    Article  CAS  PubMed  Google Scholar 

  105. de Inocencio J, et al. Somatic NOD2 mosaicism in Blau syndrome. J Allergy Clin Immunol. 2015;136(2):484-487.e2. https://doi.org/10.1016/j.jaci.2014.12.1941.

    Article  PubMed  PubMed Central  Google Scholar 

  106. Jiménez-Treviño S, González-Roca E, Ruiz-Ortiz E, Yagüe J, Ramos E, Aróstegui JI. First report of vertical transmission of a somatic NLRP3 mutation in cryopyrin-associated periodic syndromes. Ann Rheum Dis. 2013;72(6):1109–10. https://doi.org/10.1136/annrheumdis-2012-202913.

    Article  PubMed  Google Scholar 

  107. Labrousse M, et al. Mosaicism in autoinflammatory diseases: cryopyrin-associated periodic syndromes (CAPS) and beyond. A systematic review. Crit Rev Clin Lab Sci. 2018;55:432–42. https://doi.org/10.1080/10408363.2018.1488805.

    Article  CAS  PubMed  Google Scholar 

  108. Holzelova E, et al. Autoimmune lymphoproliferative syndrome with somatic Fas mutations. N Engl J Med. 2004;351(14):1409–18. https://doi.org/10.1056/NEJMoa040036.

    Article  CAS  PubMed  Google Scholar 

  109. Beck DB, et al. Somatic mutations in UBA1 and severe adult-onset autoinflammatory disease. N Engl J Med. 2020;383(27):2628–38. https://doi.org/10.1056/NEJMoa2026834.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  110. Almlöf JC, et al. Whole-genome sequencing identifies complex contributions to genetic risk by variants in genes causing monogenic systemic lupus erythematosus. Hum Genet. 2019;138(2):141–50. https://doi.org/10.1007/s00439-018-01966-7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  111. Charras A, et al. Panel sequencing links rare, likely damaging gene variants with distinct clinical phenotypes and outcomes in juvenile-onset SLE. Rheumatology. 2023;62(SI2):SI210–25. https://doi.org/10.1093/rheumatology/keac275.

    Article  PubMed  Google Scholar 

  112. Boulisfane-El Khalifi S, et al. COPA syndrome as a cause of lupus nephritis. Kidney Int Rep. 2019;4:1187–1189. https://doi.org/10.1016/j.ekir.2019.04.014.

    Article  PubMed  PubMed Central  Google Scholar 

  113. Crow YJ, AGS group. Clinical non-penetrance associated with biallelic mutations in the RNase H2 complex. J Clin Immunol. 2023;43(4):706–8. https://doi.org/10.1007/s10875-023-01438-2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  114. Javierre BM, et al. Changes in the pattern of DNA methylation associate with twin discordance in systemic lupus erythematosus. Genome Res. 2010;20(2):170–9. https://doi.org/10.1101/gr.100289.109.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  115. Garau J, et al. Altered DNA methylation and gene expression predict disease severity in patients with Aicardi-Goutières syndrome. Clin Immunol Orlando Fla. 2023;249:109299. https://doi.org/10.1016/j.clim.2023.109299.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank the patients and families. We also thank Véréna Landel for her help proofreading the manuscripts.

Funding

This research was funded by ANR (ANR-21-CE17-0064 [SOCSIMMUNITY]]), ANR-21-RHUS-08 [COVIFERON]) from the ANR–Recherche Hospitalo Universitaire Program; by the Horizon Europe (01057100 [UNDINE]) from the HORIZON-HLTH-2021-DISEASE-04; le Centre de référence des rhumatismes inflammatoires, des interféronopathies et des maladies autoimmunes (RAISE).

Author information

Author notes

  1. Maud Tusseau

    Present address: National Referee Centre for Rheumatic and AutoImmune and Systemic Diseases in Children, European Reference Network (ERN) for Rare Immunodeficiency, Autoinflammatory and Autoimmune Diseases (RITA) Center, Hospices Civils de Lyon, Lyon, France

Authors and Affiliations

  1. Centre International de Recherche en Infectiologie, Inserm, U1111, University Claude Bernard, Lyon 1, Centre National de La Recherche Scientifique, UMR5308, ENS de Lyon, Lyon, France

    Maud Tusseau, Jade Cognard, Sebastien Viel, Liliane Khoryati, Sarah Benezech, Anne-Laure Mathieu & Alexandre Belot

  2. National Referee Centre for Rheumatic and AutoImmune and Systemic Diseases in Children, European Reference Network (ERN) for Rare Immunodeficiency, Autoinflammatory and Autoimmune Diseases (RITA) Center, Hospices Civils de Lyon, Lyon, France

    Samira Khaldi-Plassart, Brigitte Bader-Meunier & Alexandre Belot

  3. Laboratory of Immunogenetics of Pediatric Autoimmune Diseases, Imagine Institute, INSERM UMR 1163, Université Paris Cité, Paris, France

    Fréderic Rieux-Laucat & Brigitte Bader-Meunier

  4. Department for Immunology, Hematology and Pediatric Rheumatology, Necker Hospital, APHP, Institut IMAGINE, Paris, France

    Brigitte Bader-Meunier

  5. Pediatric Nephrology, Rheumatology, Dermatology Unit, Hôpital Femme Mère Enfant, Hospices Civils de Lyon, Lyon, France

    Samira Khaldi-Plassart, Jade Cognard & Alexandre Belot

Authors
  1. Maud Tusseau
    View author publications

    You can also search for this author inPubMed Google Scholar

  2. Samira Khaldi-Plassart
    View author publications

    You can also search for this author inPubMed Google Scholar

  3. Jade Cognard
    View author publications

    You can also search for this author inPubMed Google Scholar

  4. Sebastien Viel
    View author publications

    You can also search for this author inPubMed Google Scholar

  5. Liliane Khoryati
    View author publications

    You can also search for this author inPubMed Google Scholar

  6. Sarah Benezech
    View author publications

    You can also search for this author inPubMed Google Scholar

  7. Anne-Laure Mathieu
    View author publications

    You can also search for this author inPubMed Google Scholar

  8. Fréderic Rieux-Laucat
    View author publications

    You can also search for this author inPubMed Google Scholar

  9. Brigitte Bader-Meunier
    View author publications

    You can also search for this author inPubMed Google Scholar

  10. Alexandre Belot
    View author publications

    You can also search for this author inPubMed Google Scholar

Contributions

M.T: Wrote the initial draft and contribute to the conceptualisation of the manuscript. S.K-P: made all the figures and did critical review of the manuscript, J.C, S.V, L.K, S.B, AL. M: did critical review of manuscript, F.R-L, B.B-M: made critically revised the manuscript and contribute to the conceptualisation of the manuscript, A.B: conceptualized the work, critically revised the manuscript and approved the version to be published.

Corresponding author

Correspondence to Alexandre Belot.

Ethics declarations

Credits

All the figures were created with BioRender.com.

Competing Interests

AB reports consulting fees from Kabi, Roche Chugai, GlaxoSmithKline, AbbVie, Novartis, and Boehringer Ingelheim; research grants from Boehringer Ingelheim, ANR, and Horizon Europe outside the scope of this comment; and is an unpaid co-chair of the French National Network on Rare Autoimmune and Autoinflammatory Diseases. All other authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tusseau, M., Khaldi-Plassart, S., Cognard, J. et al. Mendelian Causes of Autoimmunity: the Lupus Phenotype. J Clin Immunol 44, 99 (2024). https://doi.org/10.1007/s10875-024-01696-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s10875-024-01696-8

Keywords

pFad - Phonifier reborn

Pfad - The Proxy pFad of © 2024 Garber Painting. All rights reserved.

Note: This service is not intended for secure transactions such as banking, social media, email, or purchasing. Use at your own risk. We assume no liability whatsoever for broken pages.


Alternative Proxies:

Alternative Proxy

pFad Proxy

pFad v3 Proxy

pFad v4 Proxy